Bio-Path Holdings Inc (NASDAQ:BPTH)

During the Trading Day
2.41 +0.14 / +6.17%
Data as of 3:59pm ET
Day’s Change
During After-Hours   Switch to standard view »
2.41 +0.0003 / +0.01%
Volume: 62.7K
Health Technology

Company Description

Bio-Path Holdings, Inc. operates as a holding company, which through its subsidiary Bio-Path, Inc. develops novel cancer therapeutic products. It is licensed for developing three lead products and nucleric acid delivery technology, including tumor targeting technology. The company's lead product candidate, Liposomal Grb-2, is a liposomal antisense drug and is in a Phase I study for blood cancers. Its second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. Bio-Path Holdings was founded by Peter Nielsen, Gabriel Lopez-Berestein and Ana Maria Tari in May 2007 and is headquartered in Houston, TX.

Contact Information

Bio-Path Holdings, Inc.
2626 South Loop
Houston Texas 77054
P:(832) 971-6616
Investor Relations:



Mutual fund holders5.24%
Other institutional21.35%
Individual stakeholders17.25%

Top Executives

Peter H. NielsenChairman, President, CEO, CFO, Treasurer & PAO
Ulrich W. MuellerChief Operating Officer
Ana Maria TariDirector-Preclinical Operations & Research

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.